HealthCap
HealthCap is a European venture capital firm (founded 1996) that invests globally and creates companies in the life sciences. The firm focuses on breakthrough therapeutics and technologies addressing high unmet medical needs (notably rare diseases, oncology and genetic diseases). HealthCap takes an active ownership role — placing partners on boards, supporting recruitment and operational scale-up, and preparing companies for IPO or trade sale. The firm has raised multiple funds since inception and publishes ESG and SFDR disclosures.
Industries
Nr. of Employees
small (1-50)
HealthCap
Engelbrektsplan 1, 114 34 Stockholm, Sweden
Portfolio
Multiple commercial products developed, including Tracleer (bosentan, first oral PAH therapy; launched 2001), Opsumit (macitentan; launched 2013) for PAH, Uptravi (prostacyclin receptor agonist; launched 2016), Ventavis (inhaled iloprost; launched 2007) and Zavesca (miglustat; launched 2003). Actelion listed on Swiss exchange (2000) and was acquired by Johnson & Johnson (2016).
#Biopharmaceuticals (pulmonary arterial hypertension and other specialty medicines)
Spin-out from Copenhagen University developing ADCs targeting cancer-associated proteins including uPARAP.
#Biotech (antibody-drug conjugates / oncology)
Developed nitric-oxide measurement diagnostics for inflammatory airway disorders; listed on Nasdaq OMX Stockholm (2007); acquired by Circassia Pharmaceuticals (2015).
#Medical technology (diagnostics)
Developer of the Aeroneb® Pro vibrating mesh nebulizer (launched 2002). Aeroneb® Pro is a reusable, autoclavable nebulizer designed for mechanically ventilated patients and off-ventilator applications; uses Aerogen's OnQ™ aerosol generator to produce a fine-particle aerosol for hospital use.
#Medical devices (pulmonary drug delivery)
Developer of Affibody® and Albumod™ protein-engineering platforms.
#Biopharmaceuticals (protein engineering platforms)
Developer of Xofigo® (radium Ra 223 dichloride; launched 2013), an alpha-emitting radiopharmaceutical for prostate cancer with symptomatic bone metastases; listed on Oslo Stock Exchange (2007); acquired by Bayer (2014).
#Oncology (radiopharmaceuticals)
Multiple commercial products developed, including Tracleer (bosentan, first oral PAH therapy; launched 2001), Opsumit (macitentan; launched 2013) for PAH, Uptravi (prostacyclin receptor agonist; launched 2016), Ventavis (inhaled iloprost; launched 2007) and Zavesca (miglustat; launched 2003). Actelion listed on Swiss exchange (2000) and was acquired by Johnson & Johnson (2016).
#Biopharmaceuticals (pulmonary arterial hypertension and other specialty medicines)
Spin-out from Copenhagen University developing ADCs targeting cancer-associated proteins including uPARAP.
#Biotech (antibody-drug conjugates / oncology)
Developed nitric-oxide measurement diagnostics for inflammatory airway disorders; listed on Nasdaq OMX Stockholm (2007); acquired by Circassia Pharmaceuticals (2015).
#Medical technology (diagnostics)
Developer of the Aeroneb® Pro vibrating mesh nebulizer (launched 2002). Aeroneb® Pro is a reusable, autoclavable nebulizer designed for mechanically ventilated patients and off-ventilator applications; uses Aerogen's OnQ™ aerosol generator to produce a fine-particle aerosol for hospital use.
#Medical devices (pulmonary drug delivery)
Developer of Affibody® and Albumod™ protein-engineering platforms.
#Biopharmaceuticals (protein engineering platforms)
Developer of Xofigo® (radium Ra 223 dichloride; launched 2013), an alpha-emitting radiopharmaceutical for prostate cancer with symptomatic bone metastases; listed on Oslo Stock Exchange (2007); acquired by Bayer (2014).
#Oncology (radiopharmaceuticals)